NASDAQ · PETS
Healthcare · Medical - Pharmaceuticals
$1.60
Down-$0.01 (-0.31%)
Updated Sep 17, 2026, 3:26 PM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PETS closed at $1.60 after 20 trading sessions, down 9.60% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $1.63 | $1.63 | $1.60 | $1.60 | 75.5K |
| Sep 15, 2026 | $1.68 | $1.68 | $1.61 | $1.62 | 123.98K |
| Sep 14, 2026 | $1.65 | $1.69 | $1.65 | $1.67 | 93.59K |
| Sep 11, 2026 | $1.71 | $1.7499 | $1.65 | $1.65 | 37.09K |
| Sep 10, 2026 | $1.70 | $1.745 | $1.675 | $1.70 | 138.35K |
| Sep 9, 2026 | $1.73 | $1.75 | $1.71 | $1.71 | 67.01K |
| Sep 8, 2026 | $1.81 | $1.81 | $1.74 | $1.76 | 64.17K |
| Sep 4, 2026 | $1.84 | $1.84 | $1.79 | $1.81 | 49.75K |
| Sep 3, 2026 | $1.87 | $1.87 | $1.785 | $1.85 | 172.29K |
| Sep 2, 2026 | $1.84 | $1.88 | $1.84 | $1.865 | 28.82K |
| Sep 1, 2026 | $1.88 | $1.88 | $1.81 | $1.83 | 64.47K |
| Aug 31, 2026 | $1.88 | $1.9202 | $1.8654 | $1.89 | 69.99K |
| Aug 28, 2026 | $1.83 | $1.925 | $1.83 | $1.88 | 70.03K |
| Aug 27, 2026 | $1.81 | $1.87 | $1.785 | $1.85 | 67.35K |
| Aug 26, 2026 | $1.75 | $1.81 | $1.7408 | $1.79 | 101.72K |
| Aug 25, 2026 | $1.75 | $1.77 | $1.75 | $1.76 | 26.32K |
| Aug 24, 2026 | $1.76 | $1.7681 | $1.735 | $1.75 | 52.48K |
| Aug 21, 2026 | $1.78 | $1.78 | $1.7501 | $1.76 | 50.35K |
| Aug 20, 2026 | $1.77 | $1.78 | $1.75 | $1.76 | 58.32K |
| Aug 19, 2026 | $1.79 | $1.83 | $1.77 | $1.77 | 86.76K |
The latest Smart Investors Daily articles mentioning PETS.
PETS research
Company profile and research snapshot.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 17, 2025 | Morgan Stanley | Underweight | — |
| Aug 7, 2024 | Lake Street | Hold | — |
| Jun 12, 2024 | Lake Street | Buy | — |
| Jun 12, 2024 | Morgan Stanley | Underweight | — |
| Nov 16, 2023 | Morgan Stanley | Underweight | — |
No generated briefing is available yet.
prnewswire.com · Dec 11, 2025
NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. ("PetMed" or the "Company") (NASDAQ: PETS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PETS.
